Literature DB >> 9795096

Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats.

G Carta1, F Nava, G L Gessa.   

Abstract

The effects of acute and repeated administration of Delta9-tetrahydrocannabinol (Delta9-THC), the psychoactive principle of marijuana, on acetylcholine release in the hippocampus was studied in freely moving rats by microdialysis. The acute intraperitoneal (i.p.) administration of Delta9-THC at the doses of 2.5 and 5 mg/kg reduced acetylcholine release by about 25% and 45%, respectively. A dose of 7.5 mg/kg produced no further reduction. Delta9-THC effects were antagonized by the cannabinoid CB1 antagonist SR141716A at the i.p. dose of 1 mg/kg, per se ineffective in modifying acetylcholine concentrations. After a repeated exposure (twice daily for up to seven days) to Delta9-THC (7.5 mg/kg, i.p.) or vehicle (0.3 ml/kg, i.p.), the inhibitory effect of Delta9-THC (2.5 and 5 mg/kg, i.p) on acetylcholine release was not reduced. The results confirm previous observations that cannabinoids inhibit acetylcholine release through cannabinoid CB1 receptors, and indicate that no tolerance to this effects develops after a repeated Delta9-THC administration. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795096     DOI: 10.1016/s0006-8993(98)00738-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry.

Authors:  Krista Lisdahl Medina; Alecia D Schweinsburg; Mairav Cohen-Zion; Bonnie J Nagel; Susan F Tapert
Journal:  Neurotoxicol Teratol       Date:  2006-12-12       Impact factor: 3.763

2.  Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

Authors:  Anushka V Goonawardena; Lianne Robinson; Robert E Hampson; Gernot Riedel
Journal:  Learn Mem       Date:  2010-09-28       Impact factor: 2.460

3.  Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence.

Authors:  Krista Lisdahl Medina; Karen L Hanson; Alecia D Schweinsburg; Mairav Cohen-Zion; Bonnie J Nagel; Susan F Tapert
Journal:  J Int Neuropsychol Soc       Date:  2007-09       Impact factor: 2.892

4.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 5.  Cognitive function as an emerging treatment target for marijuana addiction.

Authors:  Mehmet Sofuoglu; Dawn E Sugarman; Kathleen M Carroll
Journal:  Exp Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.157

6.  D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration.

Authors:  F Nava; G Carta; A M Battasi; G L Gessa
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 7.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

Review 8.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action.

Authors:  Eleni T Tzavara; Mark Wade; George G Nomikos
Journal:  J Neurosci       Date:  2003-10-15       Impact factor: 6.167

10.  Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate.

Authors:  Anuradha Nallapaneni; Jing Liu; Subramanya Karanth; Carey Pope
Journal:  Neurotoxicology       Date:  2008-08-13       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.